Header Logo

Connection

RACHELLE DOODY to Middle Aged

Back to Details
This is a "connection" page, showing publications RACHELLE DOODY has written about Middle Aged.
RACHELLE DOODY
Connection Strength
1.176
Middle Aged
  1. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
    View in: PubMed
    Score: 0.061
  2. Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). J Alzheimers Dis. 2025 Jan; 103(2):528-541.
    View in: PubMed
    Score: 0.061
  3. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
    View in: PubMed
    Score: 0.057
  4. Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD). J Alzheimers Dis. 2024; 101(1):353-367.
    View in: PubMed
    Score: 0.057
  5. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. J Prev Alzheimers Dis. 2021; 8(1):3-6.
    View in: PubMed
    Score: 0.046
  6. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. J Prev Alzheimers Dis. 2021; 8(2):151-160.
    View in: PubMed
    Score: 0.046
  7. Gantenerumab reduces amyloid-? plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019 12 12; 11(1):101.
    View in: PubMed
    Score: 0.043
  8. Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease. PLoS One. 2016; 11(8):e0160671.
    View in: PubMed
    Score: 0.034
  9. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS Spectr. 2016 12; 21(6):450-459.
    View in: PubMed
    Score: 0.032
  10. Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living. Psychol Assess. 2015 Dec; 27(4):1234-40.
    View in: PubMed
    Score: 0.031
  11. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50.
    View in: PubMed
    Score: 0.028
  12. Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis. 2013; 34(2):449-56.
    View in: PubMed
    Score: 0.027
  13. Factor structure of the Geriatric Depression Scale and relationships with cognition and function in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 34(5-6):360-72.
    View in: PubMed
    Score: 0.026
  14. Item response theory reveals variability of functional impairment within clinical dementia rating scale stages. Dement Geriatr Cogn Disord. 2011; 32(5):362-6.
    View in: PubMed
    Score: 0.025
  15. Identifying amnestic mild cognitive impairment in primary care: a feasibility study. Clin Drug Investig. 2011; 31(7):483-91.
    View in: PubMed
    Score: 0.023
  16. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):155-9.
    View in: PubMed
    Score: 0.021
  17. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Dement Geriatr Cogn Disord. 2009; 28(1):63-9.
    View in: PubMed
    Score: 0.021
  18. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. Alzheimers Dement. 2009 Mar; 5(2):122-4.
    View in: PubMed
    Score: 0.020
  19. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
    View in: PubMed
    Score: 0.020
  20. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15.
    View in: PubMed
    Score: 0.019
  21. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008; 25(2):163-74.
    View in: PubMed
    Score: 0.019
  22. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007; 24(6):476-82.
    View in: PubMed
    Score: 0.019
  23. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord. 2005; 20(2-3):198-208.
    View in: PubMed
    Score: 0.016
  24. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005 Mar; 62(3):454-9.
    View in: PubMed
    Score: 0.015
  25. A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data. Parkinsonism Relat Disord. 2025 Mar; 132:107257.
    View in: PubMed
    Score: 0.015
  26. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
    View in: PubMed
    Score: 0.015
  27. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord. 2004 Oct-Dec; 18(4):236-40.
    View in: PubMed
    Score: 0.015
  28. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 2005; 24(1-2):42-50.
    View in: PubMed
    Score: 0.015
  29. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat Med. 2024 Apr; 30(4):1096-1103.
    View in: PubMed
    Score: 0.014
  30. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16; 389(20):1862-1876.
    View in: PubMed
    Score: 0.014
  31. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jul-Aug; 12(4):295-300.
    View in: PubMed
    Score: 0.012
  32. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul; 27(7):1187-1196.
    View in: PubMed
    Score: 0.012
  33. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):427-33.
    View in: PubMed
    Score: 0.012
  34. A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):449-54.
    View in: PubMed
    Score: 0.012
  35. Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer's Disease. J Prev Alzheimers Dis. 2021; 8(2):175-180.
    View in: PubMed
    Score: 0.012
  36. The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Arch Neurol. 1999 Sep; 56(9):1133-7.
    View in: PubMed
    Score: 0.011
  37. Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients. Alzheimer Dis Assoc Disord. 1999 Jan; 13(1):53-9.
    View in: PubMed
    Score: 0.010
  38. Alzheimer disease-related activities in China: a report from the International Working Group on the Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1998 Dec; 12(4):263-5.
    View in: PubMed
    Score: 0.010
  39. Neuropsychological asymmetry in Alzheimer's disease: verbal versus visuoconstructional deficits across stages of dementia. J Int Neuropsychol Soc. 1997 Sep; 3(5):420-7.
    View in: PubMed
    Score: 0.009
  40. Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017; 58(4):1217-1228.
    View in: PubMed
    Score: 0.009
  41. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurol. 2016 Jun 09; 16:89.
    View in: PubMed
    Score: 0.008
  42. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016 07; 28:41-48.
    View in: PubMed
    Score: 0.008
  43. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. Alzheimers Dement. 2016 Jan; 12(1):75-84.
    View in: PubMed
    Score: 0.008
  44. Positive and negative neuropsychiatric features in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(1):54-60.
    View in: PubMed
    Score: 0.008
  45. Ordered subset analysis of copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2014; 41(4):1063-71.
    View in: PubMed
    Score: 0.007
  46. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56.
    View in: PubMed
    Score: 0.007
  47. The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results. BMC Neurol. 2013 Jan 10; 13:3.
    View in: PubMed
    Score: 0.007
  48. Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dement Geriatr Cogn Disord. 2014; 37(1-2):45-57.
    View in: PubMed
    Score: 0.007
  49. Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2013; 33(2):517-23.
    View in: PubMed
    Score: 0.007
  50. Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. Transl Psychiatry. 2012 Nov 20; 2:e192.
    View in: PubMed
    Score: 0.007
  51. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
    View in: PubMed
    Score: 0.006
  52. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90.
    View in: PubMed
    Score: 0.006
  53. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011; 6(12):e28092.
    View in: PubMed
    Score: 0.006
  54. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):259-69.
    View in: PubMed
    Score: 0.006
  55. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010 Sep; 67(9):1077-81.
    View in: PubMed
    Score: 0.006
  56. Causes of aggressive behavior in patients with dementia. J Clin Psychiatry. 2010 Sep; 71(9):1145-52.
    View in: PubMed
    Score: 0.005
  57. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010 Mar 23; 74(12):956-64.
    View in: PubMed
    Score: 0.005
  58. Consequences of aggressive behavior in patients with dementia. J Neuropsychiatry Clin Neurosci. 2010; 22(1):40-7.
    View in: PubMed
    Score: 0.005
  59. Vitamin E use is associated with improved survival in an Alzheimer's disease cohort. Dement Geriatr Cogn Disord. 2009; 28(6):536-40.
    View in: PubMed
    Score: 0.005
  60. Korean version of the Baylor Profound Mental Status Examination: a brief staging measure for patients with severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(1):69-75.
    View in: PubMed
    Score: 0.005
  61. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008 Aug; 65(8):1091-5.
    View in: PubMed
    Score: 0.005
  62. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008 Mar; 4(2):145-53.
    View in: PubMed
    Score: 0.005
  63. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007 Oct 16; 69(16):1622-34.
    View in: PubMed
    Score: 0.005
  64. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
    View in: PubMed
    Score: 0.005
  65. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95.
    View in: PubMed
    Score: 0.004
  66. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38.
    View in: PubMed
    Score: 0.004
  67. Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 22(4):367-77.
    View in: PubMed
    Score: 0.004
  68. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):178-83.
    View in: PubMed
    Score: 0.004
  69. Self-reported awareness of performance in dementia. Brain Res Cogn Brain Res. 2005 Sep; 25(1):144-52.
    View in: PubMed
    Score: 0.004
  70. Factors affecting deficit awareness in persons with dementia. Dement Geriatr Cogn Disord. 2005; 20(2-3):133-9.
    View in: PubMed
    Score: 0.004
  71. Accuracy of self-reported depression in persons with dementia. J Am Geriatr Soc. 2005 Mar; 53(3):389-96.
    View in: PubMed
    Score: 0.004
  72. Dementia Deficits Scale. Rating self-awareness of deficits. Alzheimer Dis Assoc Disord. 2004 Jan-Mar; 18(1):22-31.
    View in: PubMed
    Score: 0.004
  73. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003 Dec; 60(12):1696-702.
    View in: PubMed
    Score: 0.004
  74. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
    View in: PubMed
    Score: 0.003
  75. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 03; 348(14):1333-41.
    View in: PubMed
    Score: 0.003
  76. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology. 2002 Feb 12; 58(3):433-7.
    View in: PubMed
    Score: 0.003
  77. Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement Geriatr Cogn Disord. 2002; 13(1):8-12.
    View in: PubMed
    Score: 0.003
  78. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 May; 10(3):195-203.
    View in: PubMed
    Score: 0.003
  79. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23; 283(8):1007-15.
    View in: PubMed
    Score: 0.003
  80. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11; 158(9):1021-31.
    View in: PubMed
    Score: 0.002
  81. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology. 1997 Jul; 49(1):44-50.
    View in: PubMed
    Score: 0.002
  82. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S22-32.
    View in: PubMed
    Score: 0.002
  83. Establishing the limits of the Mini-Mental State. Examination of 'subtests'. Arch Neurol. 1992 Jan; 49(1):87-92.
    View in: PubMed
    Score: 0.002
  84. Progressive nonfluent aphasia with dementia: a case report. J Geriatr Psychiatry Neurol. 1991 Oct-Dec; 4(4):236-40.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.